


PATOLOGIE OCULISTICHE - MACULOPATIA



SMD incidenza

National Eye Institute - Eye Disease Prevalence Study Group


- **The Baltimore Eye Survey, Baltimore, MD:** James M. Tielsch, Alfred Sommer, Joanne Katz, Harry A. Quigley
- **The Barbados Eye Studies, Barbados, West Indies:** M. Cristina Leske, Suh-Yuh Wu, Barbara Nemesure, Anselm Hennis, Leslie Hyman, Andrew Schachat
- **The Beaver Dam Eye Study, Beaver Dam, WI:** Barbara E.K. Klein, Ronald Klein, Kristine E. Lee, Scot E. Moss, Sandra C. Tomany



- **The Blue Mountains Eye Study, Sydney, New South Wales, Australia:** Paul Mitchell, Jie Jin Wang, Elena Rochtchina, Wayne Smith, Robert G. Cumming, Karin Attebo, Jai Panchapakesan, Suriya Foran
- **The Melbourne Visual Impairment Project, Melbourne, Australia:** Hugh R. Taylor, Cathy McCarty, Bickol Mukesh, LeAnn M. Weih, Patricia M. Livingston, Mylan Van Newkirk, Cara L. Fu, Peter Dimitrov, Matthew Wensor
- **Projecto Vision Evaluation Research, AZ:** Sheila K. West, Beatriz Muñoz, Jorge Rodriguez (deceased), Aimee T. Broman, Daniel Finklestein, Robert Snyder

Rotterdam Eye Study, Rotterdam, the Netherlands: Paulus T.V.M. de Jong, Johannes R. Vingerling, Roger C.W. Wolfs, Caroline C.W. Klaver, Albert Hofman, Redmer van Leeuwen, M. Kamran Ikram, Simone de Voogd

• **The Salisbury Eye Evaluation Project, Salisbury, MD:** Sheila West, Gary Rubin, Karen Bandeen Roche, Beatriz Muñoz, Kathy Turano, Oliver D. Schein, Donald Duncan



• Forme

Fovea = 1.5 mm

Effetti visivi: riduzione o perdita della visione centrale



“non visive” >
55 anni 34%
• Forme con
conseguenze
visive
• 60-70 anni =
12%
• 70-80 anni
35%
• > 90 anni
60%

SMD-FORME CLINICHE

- Predisposizione genetica
 - Fase senza alterazioni visive à drusen
 - Fase con riduzione visiva (mono / bilaterale)
- A) SECCA**
B) UMIDA

